4 February 2021 - Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada.
Novavax today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in the United Kingdom and United States and through initial authorization for emergency use granted under country-specific regulations.